| Today’s Big NewsNov 13, 2023 |
| By Angus Liu A few months ago, Fierce Pharma asked employees working in the biopharma industry to use photographs to tell their stories during the pandemic. Now, we’re showcasing those precious memories here. |
|
|
|
By Nick Paul Taylor Verve Therapeutics has published the first data on an in vivo base editing program in humans, giving the world an early look at the effects of a cholesterol-busting candidate that could become part of Eli Lilly’s stable of heart disease drugs. But investors pummeled the stock amid potential safety concerns. |
By Andrea Park The C-suite makeover is aimed at emphasizing ResMed’s focus on product development, profitable growth and strengthened branding, according to a company announcement. |
By Fraiser Kansteiner In 2023’s third quarter, the Israeli-American generics giant reported global sales of $3.9 billion, up 7% from the same period in 2022. The company credited that growth to the strong momentum behind its branded meds Austedo and Ajovy, plus a “stable and sustainable generics business” in the U.S. that’s also seen “continued growth” in Europe and other international markets. |
By James Waldron Novartis is going to give a solid-tumor-focused cell therapy the T-Charge treatment after paying $100 million upfront to Legend Biosciences for a selection of CAR-T candidates. |
By Conor Hale No, you didn’t set your clocks too far back. This week, the FDA granted its first full, bona fide clearance to an over-the-counter home antigen test for COVID-19, after hundreds of emergency authorizations. |
By Nick Paul Taylor GSK is building its presence in the myelofibrosis community. Working with interior designer and former "Queer Eye" star Thom Filicia, the Big Pharma is launching the Mapping Myelofibrosis health education initiative to support patients with the blood cancer treated by its recently approved drug Ojjaara. |
By Max Bayer Selecta is reverse merging with Cartesian to bolster its cash coffers and add a lifeline in a difficult public market. The focus of the new venture will be Cartesian's cell therapy aimed at autoimmune diseases. |
By Andrea Park The National Institute for Health and Care Excellence, England's cost-effectiveness watchdog, has finalized a draft guidance regarding hybrid closed-loop systems, concluding that the technology should be made broadly affordable and accessible to people with Type 1 diabetes. |
By Kevin Dunleavy Novo Nordisk has made a splash with its GLP-1 drugs that have allowed patients to achieve significant weight loss. Now the Danish company appears on the verge of another breakthrough, showing that the use of its obesity treatment Wegovy can reduce the risk of heart attack. Perhaps even more importantly, Novo said that the cardiovascular benefits gained from Wegovy aren’t due solely to weight loss. |
By Gabrielle Masson VectorY Therapeutics has secured €129 million ($138 million) in a series A financing that will help the Dutch biotech advance its preclinical lead program in ALS. |
By Conor Hale The company’s series C funding round was the first major public outing by Elevage Medical Technologies, a medtech-focused fund launched this past May with a $300 million investment from Patient Square Capital. |
Fierce podcastsDon’t miss an episode |
| | In this episode of “The Top Line,” we explore the next potential wave of mental health therapy: psychedelics. |
|
|---|
|
|
|
Tuesday, November 28, 2023 | 11am ET / 8am PT Elevate your biopharmaceutical game! Join our webinar to explore game-changing solutions. Uncover the power of Recombumin® rHA – the consistent, animal-free alternative revolutionizing manufacturing. Don't miss this chance to stay ahead in the advanced therapy landscape.
|
|
| WebinarWatch now to explore the convergence of science, capital, operational excellence and workplace strategy. Sponsored by: JLL |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| |
|
